Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Charting Microbial Ecosystem of Crohn’s Disease

Published: Thursday, March 13, 2014
Last Updated: Thursday, March 13, 2014
Bookmark and Share
Study analyzed the microbiomes of 447 newly-diagnosed patients with Crohn’s and 221 healthy individuals.

In recent years, there has been a growing awareness that our bodies are not entirely our own: each of us contains a delicate ecosystem comprised not only of human cells, but also trillions of microorganisms – bacteria, viruses, and other assorted “bugs” – that reside in our bodies. Within the human gut, as in any ecosystem, this balance can easily be disrupted, with devastating consequences.

One such consequence could be Crohn’s disease, a chronic condition that affects the gastrointestinal tract. Family history is a well-known risk factor of Crohn’s, but recent research has indicated that an abnormal immune response to the microbes in the gut also plays a role. In astudy published this week in Cell Host & Microbe, scientists have worked out which “bugs” in the gastrointestinal system are at play in the development of the disease.

The study, which was led by researchers from the Broad Institute and Massachusetts General Hospital, analyzed the microbiomes of 447 newly-diagnosed patients with Crohn’s and 221 healthy individuals. One’s microbiome includes the collective genomes of all the microorganisms that are part of the body’s ecosystem. The researchers found that several specific microbes were more prevalent in patients with Crohn’s than in their healthy counterparts, while other bugs were less common in Crohn’s cases. Addressing this dysbiosis, or imbalance, in the microbial ecosystem could be one approach to treating the disease.

Crohn’s is a form of inflammatory bowel disease (IBD) that can affect any region of the gastrointestinal tract, often causing abdominal pain, bleeding, diarrhea, and weight loss. It is an incurable condition that affects over a million people in America alone.

Ever since the microbiome was implicated in Crohn’s, researchers have been trying to understand the troublesome host-microbe interactions that may be at the root of the disease. However, identifying the key microbial players involved has been difficult.

“The challenge in past IBD microbiome studies has been that patients have been recruited at various stages of their disease. These studies captured a snapshot of a microbiome that was not only affected by disease, but also by confounding factors such as treatments or surgery. Our study accounted for these variables,” explained Ramnik Xavier, a senior associate member of the Broad and senior author of the study.

Xavier’s team was able to get a clear picture of the Crohn’s microbial ecosystem by analyzing samples collected from newly diagnosed pediatric patients from 28 different hospitals before the patients were treated for the disease. The samples, which were collected as part of a larger project funded by the Crohn’s and Colitis Foundation of America and the Helmsley Trust, revealed that certain microbiota disappeared in the guts of Crohn’s cases, including some that are thought to promote health, such as the anti-inflammatory bacteria Faecalibacterium prausnitzii. At the same time, several bacteria proliferated in Crohn’s cases, including some that have previously been linked to IBD and one that is known to promote colorectal cancer.

“Knowing these key players is a good starting point for developing therapeutics that target these bugs. We now have a detailed list of organisms to pursue in future studies,” said first author Dirk Gevers, group leader of Microbial Systems and Communities in the Broad’s Genome Sequencing and Analysis Program.

Since three types of samples were collected consistently across all 28 hospitals – biopsied tissue from the ileum (located at the end of the small intestine) and rectum (at the end of the large intestine), as well as stool samples – the researchers were able to determine which sample types were predictive of disease. They found that stool samples were poor predictors, whereas both tissue samples were predictive of Crohn’s no matter where in the gut the patients had the disease. Since the rectum is at the end of the digestive tract, this finding opens up the possibility of using rectal tissue samples as a relatively non-invasive diagnostic test for Crohn’s.

The researchers also noted another interesting finding: while the patients sampled had not yet started on treatment for Crohn’s, roughly 10 percent had been given antibiotics to treat inflammation prior to diagnosis – just before their samples were collected and recently enough for those samples to be affected by the drugs. These patients tended to have an even greater imbalance in their gut microbiota than did other patients, suggesting that follow-up studies should be conducted to determine whether the standard antibiotic treatments for early symptoms of Crohn’s are as beneficial as intended.

Xavier, who is also the chief of the gastrointestinal unit and director of the Center for Inflammatory Bowel Disease at Massachusetts General Hospital and the Kurt Isselbacher Professor of Medicine at Harvard Medical School, said that the next order of business for his team would be to try to determine exactly how the bugs they identified are connected to genes and disease.

“Now that we’ve identified the key organisms at work in Crohn’s, we want to get a functional understanding of the role these microbes and microbial products play in the disease. I think that’s where we’re going to be putting out efforts in the near future,” he said.

This work was supported by the Crohn’s and Colitis Foundation of America, the Army Research Office, the National Institutes of Health, and the Helmsley Trust.

Other Broad researchers who contributed to the study include Curtis Huttenhower, Moran Yassour, Aleksander Kostic, Chengwei Luo, Xochitl Morgan, and Emma Schwager, in collaboration with researchers from several other institutions. Analysis was conducted in conjunction with Curtis Huttenhower’s lab at the Broad and Harvard School of Public Health, and Rob Knight’s lab at the University of Colorado, Boulder.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DARPA Awards $32 Million Contract to MIT, Broad Institute Foundry
A facility at the Broad Institute of MIT and Harvard and MIT that aims to achieve the full potential of engineering biology has received a five-year, $32 million contract from the Defense Advanced Research Projects Agency (DARPA).
Monday, September 28, 2015
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
Monday, September 28, 2015
Scientists Discover New System For Human Genome Editing
CRISPR-Cpf1 system could disrupt both scientific and commercial landscape.
Monday, September 28, 2015
Researchers Develop a New Means of Killing Harmful Bacteria
Engineered particles are capable of producing toxins that are deadly to targeted bacteria.
Friday, June 26, 2015
Broad Institute & Google Genomics Combine Bioinformatics and Computing Expertise
Both companies explore how to break down major technical barriers that increasingly hinder biomedical research.
Thursday, June 25, 2015
CRISP-Disp Leverages CRISPR-Cas9 to Deliver RNA Structures to Targets in the Genome
A team of researchers from the Broad Institute and the Harvard Stem Cell Institute has developed CRISP-Disp, a method that expands on the CRISPR-Cas9 system, allowing researchers to display multiple, large RNA structures on the Cas9 protein.
Wednesday, June 10, 2015
GTEx: Useful Expression For Cancer Research
GTEx Project has recently published several papers reporting on findings from its two-year pilot phase.
Tuesday, May 26, 2015
Single-cell Analysis Hits its Stride
Advances in technology and computational analysis enable scale and affordability, paving the way for translational studies.
Saturday, May 23, 2015
Highly Efficient New Cas9 for In Vivo Genome Editing
New finding is expected to expand therapeutic and experimental applications of CRISPR.
Tuesday, April 07, 2015
Broad Institute of MIT and Harvard and Bayer Healthcare Expand their Partnership
Collaboration to develop therapies for cardiovascular disease.
Thursday, April 02, 2015
In vivo CRISPR-Cas9 Screen Sheds Light On Cancer Metastasis And Tumor Evolution
Genome-scale study points to drivers of tumor evolution and metastasis, provides roadmap for future in vivo Cas9 screens.
Friday, March 06, 2015
Scientists Map the Human Loop-ome, Revealing a New Form of Genetic Regulation
Researchers describe the results of a five-year effort to map, in unprecedented detail, how the 2-meter long human genome folds inside the nucleus of a cell.
Tuesday, December 23, 2014
Disorder in Gene-Control System is a Defining Characteristic of Cancer, Study Finds
Findings indicate that the disarray in the on-off mechanism is one of the defining characteristics of cancer.
Tuesday, December 23, 2014
Two Studies Identify A Detectable, Pre-Cancerous State In The Blood
Findings pave way for new lines of cancer research focused on detection and prevention.
Thursday, November 27, 2014
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Friday, October 10, 2014
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos